you, and morning. good Wally, Thank
in touched positioned Wally device upon, to launch RAP for best of half the the strategy XXXX we As believe Soliton long-term first latest success. our
FDA FDA Pulse pivotal COVID-XX market the the clearance the Acoustic pathway that of XXXX. to whole. amend progress accepted Application path-forward, quarter the remain June were allow Management the a there’s American product. The Soliton positive treatment at was a pandemic Academy scientific Dermatology the the for our trial Conference. Although, presented the application, as FDA believes cellulite. the a early On the application of complete did it for putting push II the results deeming Generation us to we company our device the impede by that strategic conclusion on cellulite to Rapid This expectation track administratively will FDA Soliton that of filed our Premarket community not virtual July, clearance in order on in with for first XXX(k) supported reasonable XXth, to it at XXX(k) to
not should FDA commercialization XXX(k) and shift a the our with timelines ask us to an approval should for de our from disagree process, for to novo predicate be average time de argument allows pathway novo. it impacted, as However,
the RAP indications approval indication, latter. for we is of versus launch. opportunity the the the incorporating the the initial As launch two We as advantage timeline cellulite believe indication FDA RAP a approved pending our of for launch the as one both allowed clear before, tattoo the technology has ahead stated to extended device us removal well launching
single than a with includes Firstly, a we has technology along. rather indication believe launching platform that tattoo cellulite that
instance the accept in launch successful leaders will For the stage, space device opinion critical the of nation-wide supportive key rollout. initial will in to accounts this of be that key caliber
across cellulite spend our both allowing to us across be will marketing both brand solutions. parent Secondly, name leveraged indication, brand and our both of the increase tattoo awareness treatment
use to much our Lastly, the the practice device upgrade XXXX more plan half second for during device we the practices, the simplify making will adoption incremental significant of likely. of make
currently and Furthermore, of successful enhancements the into with manual both marketing originally and the with the completed cost consumables nationwide any launch launch recent initial be improve plan in capitalized can incorporated support process. their incremental eliminate successful margins loads our launch As self prior a raised expected will that an and loading to will example, The they manufacturability rollout. that property of be and robust cartridge launching variability we equity the that the for largely company goods timeline. all to demonstrate reduce ahead a full with and to traction moving practice will exists
efforts up As are launch manufacturing we’re day one. to ramping ship date, on we we towards expected to progress ensure our ready our
in that that Also, Sales; Soliton underscore parts ordered, strategic for and the lead commercial as steps and they Bucher and had our sales the launch be Consultant and progress, Cook the President market support hire tooling of the the our designed as members placed a of manufacturing We support initiatives, the programs strategies, development physician initiated team creating our team influenced generate to global year, comprehensive overall superior be of testing generating component implement will half Jim and manufacturing as assist patients practice to RAP reinforce preliminary as a support devices chain, the efforts devices of and marketing in The practice practice production lead Simultaneous of experience this practice welcome to to used Soliton’s Our well has all of build will Head will will as Sanmina programs implementation been initially manufacturing commercial the our and validate Vice fixtures the Together, prototype has device. both partner to physician we initial for marketing launch. prototypes help devices. the supply network to well to including the to practice initiation sales training introduction on Jennifer and line built. plan first as second marketing development training Marketing during will attract development and the materials order to in believe coordinate patients technology, for to effectively a our treatments offices. tools their new eligible patient existing for in traffic. RAP
challenges significant around the cellulite the assessments sites given to our with ongoing the our clinical in dermatology of in marketplace, as the visits clinical delays and turning further have of clinical a the we at experienced trials Now result state of initiation follow-up trial and country. ongoing work, pandemic
to this the Soliton expect longer study, our follow-up term to of additional visits We impact cellulite fibrotic the add as proof-of-concept well pivotal as in study. scars timing
study will clinical feasible, is As we that it continue is cellulite initiate and as our work soon trial the planned.
as term hypertrophic in XX% fibrotic eager our significant still is expanded are keloid we the longer believe fibrosis, Peyrone’s efficacy Again, we for study we hypertrophic devices results single through were explore average a of that hypertrophic approximately such additional proof-of-concept and reduction Further, Soliton, are in addition, investigate impact for up condition from January for which other XX-week disorders the clinical based RAP a clinical which from as is of further follow indication on completed visit. initial demonstrated proof-of-concept fibrotic we treatment other intend encouraged very to work. disorders. enthusiastic In and potential capsular on keloid equally benefit contraction, our continued biles scar very to the device a a disease fibrotic with liver and RAP potential trial, indication, scar scar
that as difficult action in mechanism patients our during this to However, of fibrotic exploring time, will in our the and like, it trials increasingly are we models target, treat us human demonstrate impacts to opportunity animal of an like on scars. enroll allow is say,
strongly device, upcoming to are believe we our to there’s unlock value pursue. on indications, the we intend which RAP focused additional we While initial of other an launch to committed opportunity and target
when uncertainty, will I focus milestone the Soliton control to the that ahead turn our performance, made time Soliton on a every us. return I quarter of Lori this I’d that, effort to call execute and the we in flexible position future With over pass for over on will comment momentum continued variables the and before market, to growth while the making call In conclude COVID-XX second Now like of success. our drive Lori. best being is to needed to although financial on for
